Comparison of the predictive value of pathological response at primary tumor and lymph node status after neoadjuvant chemotherapy in locally advanced gastric cancer

[1]  T. Takayama,et al.  Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives , 2022, Biomedicines.

[2]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  X. Ying,et al.  Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy , 2021, World journal of gastrointestinal oncology.

[4]  J. Ji,et al.  Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised c , 2021, The Lancet. Oncology.

[5]  Laura H. Tang,et al.  Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence , 2021, Annals of Surgical Oncology.

[6]  M. Gualtierotti,et al.  Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single‐center experience , 2021, Journal of surgical oncology.

[7]  J. Ji,et al.  The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial , 2021, BMC cancer.

[8]  Chang-ming Huang,et al.  Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study. , 2020, The oncologist.

[9]  Jianjun Zhang,et al.  Tumor Regression Grade Predicts Survival in Locally Advanced Gastric Adenocarcinoma Patients with Lymph Node Metastasis , 2020, Gastroenterology research and practice.

[10]  J. Ajani,et al.  Tumor Regression Grade in Gastric Cancer After Preoperative Therapy , 2020, Journal of Gastrointestinal Surgery.

[11]  J. Ajani,et al.  Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer , 2020, Journal of surgical oncology.

[12]  W. Kang,et al.  Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines , 2020, World journal of gastrointestinal oncology.

[13]  B. Zilberstein,et al.  Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer , 2019, Journal of surgical oncology.

[14]  M. Westerhoff,et al.  Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey , 2019, Modern Pathology.

[15]  Yan Zhao,et al.  Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response , 2019, Cancer Chemotherapy and Pharmacology.

[16]  M. Egger,et al.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.

[17]  L. Xue,et al.  Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy , 2019, World journal of gastrointestinal oncology.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  H. Lee,et al.  Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System , 2018, Cancers.

[20]  Lianhai Zhang,et al.  Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis , 2018, PloS one.

[21]  R. Pugliese,et al.  Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. , 2017, Journal of gastrointestinal oncology.

[22]  M. O’Donovan,et al.  Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma , 2017, The British journal of surgery.

[23]  K. Ott,et al.  Prognostic impact of nodal status and therapeutic implications. , 2017, Translational gastroenterology and hepatology.

[24]  C. Hollenbeak,et al.  Tumor regression grade in gastric cancer: Predictors and impact on outcome , 2016, Journal of surgical oncology.

[25]  H. Grabsch,et al.  Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Lordick,et al.  Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients , 2012, Annals of Surgical Oncology.

[27]  Wen-xian Hu,et al.  Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer , 2012, Journal of surgical oncology.

[28]  Rong-yue Teng,et al.  Reduced Lymph Node Harvest after Neoadjuvant Chemotherapy in Gastric Cancer , 2011, The Journal of international medical research.

[29]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[31]  H. Höfler,et al.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.

[32]  Wentao Liu,et al.  Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. , 2021, American journal of translational research.